DBV Technologies S.A. (DBVTF) SEC Filings

DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a sale of 464 ordinary shares on July 29, 2026 at $2.70 per share. The shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units. After this transaction, Pharis directly held 144,531 ordinary shares, which may be represented by American Depositary Shares, each currently representing five ordinary shares.

DBV Technologies S.A. is establishing an automatic shelf registration statement on Form S-3, allowing the company and any selling securityholders to offer, from time to time, an indeterminate amount of ordinary shares, ADSs representing ordinary shares, and warrants. The registration is filed as a well-known seasoned issuer shelf, with no limit on the aggregate amount of securities that may be offered under this program.

Offerings may be primary sales by DBV or resales by selling securityholders and can be conducted in various ways, including direct sales, offerings through agents, or through underwriters and dealers on a continuous or delayed basis. DBV’s ADSs trade on Nasdaq under “DBVT,” with a last reported price of $13.86 per ADS on July 23, 2026, and its ordinary shares trade on Euronext Paris under “DBV” at €2.374 per share on the same date; warrants are not listed on any market. Unless specified otherwise in a supplement, DBV will use net proceeds from its own offerings for working capital and general corporate purposes and will not receive proceeds from sales by selling securityholders.

The prospectus also summarizes DBV’s business as a late stage specialty biopharmaceutical company developing its Viaskin epicutaneous immunotherapy platform, including Viaskin Peanut patches for children with peanut allergy. As of July 23, 2026, DBV had 296,085,697 ordinary shares issued and outstanding, fully paid, with no preferred shares. Extensive disclosure is provided on French corporate law, shareholder rights, ADS terms, and ownership and notification thresholds that apply to DBV’s equity securities.

DBV Technologies reported second-quarter and half-year 2026 results, highlighting continued investment in its VIASKIN® Peanut Patch program and commercial readiness. Under U.S. GAAP, operating income was $1.6 million for the first half of 2026, while operating expenses rose to $100.1 million, driven by higher R&D, sales and marketing, and general and administrative costs.

The company recorded a half-year net loss of $98.0 million and basic/diluted net loss per share of $(0.23), compared with $(0.58) a year earlier, reflecting a significantly strengthened equity base. Net cash used in operating and investing activities increased to $102.6 million. Cash and cash equivalents were $174.9 million as of June 30, 2026, and management currently forecasts funding into the third quarter of 2027, assuming continued focus on the VIASKIN® Peanut Patch and related regulatory and commercial activities, including a planned BLA submission in the third quarter of 2026.

DBV Technologies S.A. is a late-stage biopharmaceutical company developing the Viaskin epicutaneous patch platform, led by Viaskin Peanut for children with peanut allergy. For the quarter ended June 30, 2026, there was no product revenue; operating income of $0.7 million came solely from the French research tax credit.

Quarterly operating expenses were $51.3 million, including research and development of $31.2 million, sales and marketing of $5.5 million, and general and administrative of $14.6 million, reflecting scaling for Biologics License Application (BLA) execution and commercial launch preparedness. Net loss was $50.4 million for the quarter and $98.0 million for the first six months, with basic and diluted loss per share of $(0.12) and $(0.23), respectively.

Cash and cash equivalents totaled $174.9 million at June 30, 2026. Net cash used in operating activities was $101.7 million and in investing activities $0.9 million in the first half, partially offset by $89.0 million of financing inflows from warrant exercises linked to the March 2025 PIPE financing. Management estimates existing resources will fund operations into the third quarter of 2027. The company is preparing a BLA for Viaskin Peanut in children aged 4–7 years in the third quarter of 2026 and a potential toddler BLA in the second half of 2026, supported by expanded manufacturing agreements and commercialization letters of intent.

DBV Technologies S.A. provided an update on its planned Biologics License Application (BLA) seeking U.S. marketing approval for the VIASKIN® Peanut Patch in children aged four through seven years. After detailed, collaborative discussions with the FDA on data organization and formatting, the agency has not requested additional data. DBV will use the feedback to refine the submission and now anticipates filing the BLA in the third quarter of 2026. The company will discuss the update on a conference call and webcast on June 29 at 5:00 p.m. ET.

DBV Technologies S.A. approved a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 4,060,000 Performance Share Units (PSUs). Each PSU is a conditional right to receive one ordinary share.

Vesting depends on FDA approval of biologics license applications for Viaskin Peanut in specified age groups and a continued employment condition through July 1, 2028. PSUs that do not meet performance conditions by this date are forfeited. Vested shares are scheduled for delivery in four installments on July 1, 2028, January 1, 2029, July 1, 2029 and January 1, 2030.

Upon a Change in Control, performance conditions are deemed achieved and only the employment condition remains. The plan includes special rules for death, disability, qualifying retirement, termination without cause or for good reason, Section 409A deferral for specified employees, and allows the Board to substitute equivalent cash if the CEO is not a French tax resident at delivery.

DBV Technologies S.A. reported the results of its Annual Combined Meeting of Shareholders and related changes to its bylaws. Shareholders approved amendments to Articles 18 and 21 to align the Ordinary Share Record Date with French decree nº2026-94 of February 13, 2026. They also amended Article 15 to set a Chief Executive Officer age limit of 70 years, with the CEO’s mandate ending at the shareholders’ meeting approving the financial statements for the year in which that age is reached. Across the ordinary and extraordinary agendas, the thirty-nine proposals received strong support, with many resolutions attracting around 190 million votes in favor versus much smaller opposition, confirming broad shareholder backing for the updated governance framework.

DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.

Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.

The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.